Residual or retained gadolinium: Practical implications for radiologists and our patients

Radiology

Volumn 275, Issue 3, 2015, Pages 630-634

  Kanal, Emanuel ^a   Tweedle, Michael F ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM CHLORIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; CONTRAST MEDIUM; MEGLUMINE; ORGANOMETALLIC COMPOUND;

BENIGN TUMOR; BLOOD BRAIN BARRIER; CARDIOTOXICITY; CONTRAST ENHANCEMENT; DENTATE NUCLEUS; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; EDITORIAL; FATTY LIVER; GLOBUS PALLIDUS; GLOMERULUS FILTRATION RATE; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; KIDNEY FUNCTION; MASS SPECTROMETRY; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGIST; RISK ASSESSMENT; BRAIN; CEREBELLUM NUCLEUS; FEMALE; MALE; METABOLISM;

BRAIN; CEREBELLAR NUCLEI; CONTRAST MEDIA; FEMALE; GADOLINIUM; GADOLINIUM DTPA; GLOBUS PALLIDUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 84930845069     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015150805     Document Type: Editorial

References (29)

1. Bleicher AG, E. Kanal E., Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191(6):W307-311.
2. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108. [Published correction appears in Nephrol Dial Transplant 2006;21(6):1745.]
3. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17(9):2359-2362.
4. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270(3):834-841.
5. Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49(10):685-690.
6. Kanda, T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology doi: 10.1148/radiol.14140364, Published online January 27, 2015.
7. Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol doi: 10.1097/RLI.0000000000000154. Published online March 11, 2015.
8. Wedeking P, Sotak CH, Telser J, Kumar K, Chang CA, Tweedle MF. Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat. Magn Reson Imaging 1992;10(1):97-108.
9. Radbruch A, Weberling LD, Pascal J, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology doi: 10.1148/radiol.2015150337. Published online April 6, 2015.
10. Brunberg JA, Kanal E, Hirsch W, Van Thiel DH. Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T. AJNR Am J Neuroradiol 1991;12(5):909-914.
11. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology doi: 10.1148/radiol.15150025. Published online March 5, 2015.
12. Kanda, T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology (in press).
13. Ball RA, Van Gelder G, Green JW Jr, Reece WO. Neoplast Ic sequelae following subcutaneous implantation of mice with rare earth metals. Proc Soc Exp Biol Med 1970;135(2):426.
14. Lazar G. Effect of reticuloendothelial stimulation and depression on rare-earth metal chloride-induced splenic calcification and fatty degeneration of liver. Experientia 1973;29(7):818-819.
15. Biagi BA, Enyeart JJ. Gadolinium blocks low-threshold and high-threshold calcium currents in pituitary cells. Am J Physiol 1990;259(3):C515-C520.
16. Molgo J, del Pozo E, Baños JE, Angaut-Petit D. Changes of Quantal transmitter release caused by gadolinium ions at the frog neuromuscular junction. Br J Pharmacol 1991;104(1):133-138.
17. Adding LC, Bannenberg GL, Gustafsson LE. Basic experimental studies and clinical aspects of gadolinium salts and chelates. Cardiovasc Drug Rev 2001;19(1): 41-56.
18. Gries H. Extracellular MRI contrast agents based on gadolinium. In: Krause W, ed. Topics in current chemistry. Heidelberg, Germany: Springer-Verlag, 2002.
19. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8(4):467-481.
20. Tweedle MF, Gaughan GT, Hagan J, et al. Considerations involving paramagnetic coordination-compounds as useful NMR contrast agents. Int J Rad Appl Instrum B 1988;15(1):31-36.
21. Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43(12):817-828.
22. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30(6):372-380.
23. Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committee 2009, Bethesda, MD. U.S. Food and Drug Administration Web site. http://www.fda.gov/AdvisoryCommittees/CommitteesMeeting-Materials/Drugs/CardiovascularandRenal-DrugsAdvisoryCommittee/ucm125999.htm. Published 2009.
24. Edwards BJ, Laumann A, Nardone B, et al. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol doi: 10.1259/bjr.20140307. Published online September 17, 2014.
25. Bayer-HealthCare-Pharmaceuticals. Briefing document for gadobutrol injection NDA 201,277, 2011, to the Peripheral & Central Nervous System Drugs Advisory Committee of the Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240357.pdf.
26. Birka M, Wentker KS, Lusmöller E, et al. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem 2015;87(6): 3321-3328.
27. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004;39(3):138-142.
28. White GW, Gibby WA, and Tweedle MF, Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41(3):272-278.
29. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009;1(6):479-488.